Format
Items per page
Sort by

Send to:

Choose Destination

Results: 16

1.

Fesoterodine Clinical Efficacy and Safety for the Treatment of Overactive Bladder in Relation to Patient Profiles: A Systematic Review.

Chapple C, Oelke M, Kaplan SA, Scholfield D, Arumi D, Wagg AS.

Curr Med Res Opin. 2015 Mar 23:1-78. [Epub ahead of print]

PMID:
25798911
2.

Review of the efficacy and safety of fesoterodine for treating overactive bladder and urgency urinary incontinence in elderly patients.

Wagg A, Oelke M, Angulo JC, Scholfield D, Arumi D.

Drugs Aging. 2015 Feb;32(2):103-25. doi: 10.1007/s40266-014-0237-6.

PMID:
25673122
3.

Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER.

Kaplan SA, Cardozo L, Herschorn S, Grenabo L, Carlsson M, Arumi D, Crook TJ, Whelan L, Scholfield D, Ntanios F; Assessment of Fesoterodine after Tolterodine ER (AFTER) Study Group.

Int J Clin Pract. 2014 Sep;68(9):1065-73. doi: 10.1111/ijcp.12464. Epub 2014 Jun 4.

4.

An observational study of patient satisfaction with fesoterodine in the treatment of overactive bladder: effects of additional educational material.

Schneider T, Arumi D, Crook TJ, Sun F, Michel MC.

Int J Clin Pract. 2014 Sep;68(9):1074-80. doi: 10.1111/ijcp.12450. Epub 2014 May 5.

PMID:
24797765
5.

Flexible dosing with fesoterodine 4 and 8 mg: a systematic review of data from clinical trials.

Wyndaele JJ, Schneider T, MacDiarmid S, Scholfield D, Arumi D.

Int J Clin Pract. 2014 Jul;68(7):830-40. doi: 10.1111/ijcp.12425. Epub 2014 Apr 22.

6.

[Psychometric validation of the OAB-V8 and OAB-V3 scales for the screening of patients with probable overactive bladder in the Spanish population].

Brenes FJ, Angulo JC, Ochayta D, Rejas J, Arumí D, Cañadas A, Lizarraga I.

Med Clin (Barc). 2014 Dec 23;143(12):521-9. doi: 10.1016/j.medcli.2013.10.032. Epub 2014 Apr 13. Spanish.

PMID:
24725856
7.

Factors associated with dose escalation of fesoterodine for treatment of overactive bladder in people >65 years of age: A post hoc analysis of data from the SOFIA study.

Wagg A, Darekar A, Arumi D, Khullar V, Oelke M.

Neurourol Urodyn. 2014 Apr 3. doi: 10.1002/nau.22603. [Epub ahead of print]

PMID:
24706493
8.

The effect of hyperactive bladder severity on healthcare utilization and labor productivity.

Angulo JC, Brenes FJ, Ochayta D, Lizarraga I, Arumí D, Trillo S, Rejas J.

Actas Urol Esp. 2014 May;38(4):249-56. doi: 10.1016/j.acuro.2013.11.002. Epub 2014 Jan 23. English, Spanish.

PMID:
24462234
9.

Therapeutic benefit in patients switching tolterodine to other novel antimuscarinic agents.

Sánchez-Ballester F, Miranda P, Lizarraga I, Rejas J, Arumi D.

Actas Urol Esp. 2014 Apr;38(3):156-63. doi: 10.1016/j.acuro.2013.07.008. Epub 2013 Oct 8. English, Spanish.

PMID:
24119382
10.

Effects of drug cessation after flexible-dose fesoterodine in patients with overactive bladder.

Khullar V, Cardozo L, Kelleher CJ, Hall T, Ryan J, Ebel Bitoun C, Darekar A, Arumi D, Wagg A.

BJU Int. 2013 Oct;112(6):820-9. doi: 10.1111/bju.12006. Epub 2013 Mar 7.

PMID:
23465055
11.

Predicting self-perceived antimuscarinic therapy effectiveness on overactive bladder symptoms using the Overactive Bladder 8-Question Awareness Tool.

Villacampa F, Ruiz MA, Errando C, Arlandis S, Arumí D, Lizarraga I, Rejas J.

Int Urogynecol J. 2013 Apr;24(4):573-81. doi: 10.1007/s00192-012-1921-x. Epub 2012 Oct 31.

PMID:
23111865
12.
13.

Quality of life in patients with overactive bladder: validation and psychometric properties of the Spanish Overactive Bladder Questionnaire-short Form.

Arlandis S, Ruiz MA, Errando C, Villacampa F, Arumí D, Lizarraga I, Rejas J.

Clin Drug Investig. 2012 Aug 1;32(8):523-32. doi: 10.2165/11633760-000000000-00000.

PMID:
22741748
14.

Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: a decision-tree model.

Arlandis-Guzman S, Errando-Smet C, Trocio J, Arumi D, Rejas J.

BMC Urol. 2011 May 20;11:9. doi: 10.1186/1471-2490-11-9.

15.

[Assessment of reasons for overactive bladder treatment change].

Castro D, Miranda P, Sánchez-Ballester F, Arumi D, Lizarraga I, Ebel C; grupo de estudio Impacta.

Actas Urol Esp. 2011 Feb;35(2):73-9. doi: 10.1016/j.acuro.2010.11.011. Spanish.

PMID:
21296454
16.

[Prevalence of urinary incontinence and hyperactive bladder in the Spanish population: results of the EPICC study].

Martínez Agulló E, Ruiz Cerdá JL, Gómez Pérez L, Ramírez Backhaus M, Delgado Oliva F, Rebollo P, González-Segura Alsina D, Arumi D; Grupo de Estudio Cooperativo EPICC.

Actas Urol Esp. 2009 Feb;33(2):159-66. Spanish.

PMID:
19418840
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk